Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. (AQST): 11 pipeline candidates · 12 upcoming catalysts · ~24 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
23.6 months
D/E -5.14 · 0% dilution
Lead: Approved
11 candidates
12 upcoming, next in ~167d
0 buys · 8 sells (180d)
A transparent, data-derived signal for Aquestive Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$523.1M
Cash
$110.7M
Quarterly Burn
$14.8M
Runway
23.6 mo
Revenue
$14.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| anaphylm | BLA Filed |
| anaphylm sublingual film | — |
| Anaphylm™ | Phase 3 |
| AQST-108 | Phase 1 |
| emylif | — |
| Emylif® (licensed product, formerly Exservan® in U.S.) | Approved |
| libervant | Approved |
| Libervant® | Approved |
| nda | Approved |
| Ondif® (licensed product) | Approved |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (12)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
179
Total value held
$318.4M
| Holder | Shares | Value |
|---|---|---|
| bratton capital management, l.p. | 9,810,958 | $40.7M |
| blackrock, inc. | 7,509,071 | $31.2M |
| rtw investments, lp | 7,426,471 | $30.8M |
| vanguard capital management llc | 4,443,698 | $18.4M |
| arete wealth advisors, llc | 121,485 | $14.1M |
| federated hermes, inc. | 2,940,339 | $12.2M |
| balyasny asset management l.p. | 2,900,570 | $12.0M |
| state street corp | 2,546,191 | $10.6M |
| samsara biocapital, llc | 2,500,000 | $10.4M |
| geode capital management, llc | 2,408,191 | $10.0M |
Showing top 10 of 179 institutional holders of Aquestive Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Aquestive Therapeutics, Inc.'s pipeline?
Aquestive Therapeutics, Inc. (AQST) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aquestive Therapeutics, Inc.'s lead drug candidate?
Aquestive Therapeutics, Inc.'s most advanced tracked candidate is anaphylm (BLA Filed) for severe allergic reactions, including anaphylaxis.
What is Aquestive Therapeutics, Inc.'s next catalyst?
Aquestive Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: CLINDESSE" — expected December 2, 2026.
What is Aquestive Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aquestive Therapeutics, Inc. has approximately 23.6 months of cash runway.
What is Aquestive Therapeutics, Inc.'s market capitalization?
Aquestive Therapeutics, Inc.'s market capitalization is approximately $523.1M.
Get the full picture on Aquestive Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.